Clinical Drug Investigation

, Volume 29, Issue 12, pp 811–819 | Cite as

Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism

A Prospective Cohort Study in Primary Care
  • Ken Yajima
  • Akira Shimada
  • Hiroshi Hirose
  • Yoichi Oikawa
  • Satoru Yamada
  • Shu Meguro
  • Junichiro Irie
  • Seiko Irie
Original Research Article
  • 32 Downloads

Abstract

Background and Objective: Renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]), are recommended by the American Diabetes Association for blood pressure control and prevention or management of cardiovascular disease in patients with diabetes mellitus. However, some investigators have suggested that ARBs may increase the risk of myocardial infarction in hypertensive patients. Activation of the RAS is associated with an increased risk of ischaemic events. Angiotensin II stimulates the production of plasminogen activator inhibitor type-1 (PAI-1), a powerful predictor of cardiovascular disease. ACE inhibitors are reported to reduce PAI-1 levels and activity, while ARBs do not reduce or may even elevate levels of this atherogenic marker. The objective of this study was to determine whether the ACE inhibitor imidapril reduces PAI-1 levels in hypertensive patients already being treated with an ARB.

Methods: This was a prospective cohort study carried out in primary care with a follow-up period of 6 months. Estimating the α error (p-value) at 0.05, the power of the test as 80%, and the difference in PAI-1 levels as 10 ±15ng/mL, the required sample size was calculated to be 40. Participants were hypertensive patients taking ARBs for more than 8 weeks, and having dyslipidaemia, obesity or abnormal glucose metabolism. Imidapril 5–10 mg/day was prescribed for 6 months to reduce blood pressure to < 130/80 mmHg. The main outcome measure, PAI-1 level, was measured before and 6 months after the addition of imidapril to ARBs in 21 subjects (13 men, eight women), all with abnormal glucose metabolism, nine with dyslipidaemia, and six who were obese. Bodyweight, body mass index, blood pressure, homeostasis model assessment of insulin resistance, glycosylated haemoglobin, creatinine, potassium, high sensitivity C-reactive protein (hs-CRP), and high molecular weight adiponectin levels were measured as secondary outcomes.

Results: PAI-1 level was not significantly changed overall. Hs-CRP level was also not significantly changed; however, the high molecular weight adiponectin level was significantly increased (p = 0.044), especially in men (p = 0.026). There were no significant changes in the other outcomes measured.

Conclusion: The current study showed that imidapril added to ARBs did not decrease PAI-1 levels in hypertensive patients with abnormal glucose metabolism; however, this combination therapy significantly increased high molecular weight adiponectin levels in men.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2008; 31Suppl. 1: S12–54CrossRefGoogle Scholar
  2. 2.
    Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329: 1248–9PubMedCrossRefGoogle Scholar
  3. 3.
    Cheung BM, Cheung GT, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 2006; 20: 37–43PubMedCrossRefGoogle Scholar
  4. 4.
    Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381–6PubMedCrossRefGoogle Scholar
  5. 5.
    McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005; 331: 873PubMedCrossRefGoogle Scholar
  6. 6.
    Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005; 23: 2113–8PubMedCrossRefGoogle Scholar
  7. 7.
    Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006; 114: 855–60PubMedCrossRefGoogle Scholar
  8. 8.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35CrossRefGoogle Scholar
  9. 9.
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10PubMedCrossRefGoogle Scholar
  10. 10.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91CrossRefGoogle Scholar
  11. 11.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53PubMedCrossRefGoogle Scholar
  12. 12.
    Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130–1PubMedCrossRefGoogle Scholar
  13. 13.
    Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother 2005; 39: 470–80PubMedCrossRefGoogle Scholar
  14. 14.
    Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951–8PubMedCrossRefGoogle Scholar
  15. 15.
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114: 838–54PubMedCrossRefGoogle Scholar
  16. 16.
    Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–8PubMedCrossRefGoogle Scholar
  17. 17.
    Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940–3PubMedCrossRefGoogle Scholar
  18. 18.
    Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–41PubMedCrossRefGoogle Scholar
  19. 19.
    Salomaa V, Stinson V, Kark JD, et al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study: Atherosclerosis Risk in Communities Study. Circulation 1995; 91: 284–90PubMedCrossRefGoogle Scholar
  20. 20.
    Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108: 391–4PubMedCrossRefGoogle Scholar
  21. 21.
    Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–104PubMedCrossRefGoogle Scholar
  22. 22.
    Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995–1001PubMedCrossRefGoogle Scholar
  23. 23.
    Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285–90PubMedCrossRefGoogle Scholar
  24. 24.
    Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–801PubMedCrossRefGoogle Scholar
  25. 25.
    Brown NJ, Kumar S, Painter CA, et al. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40: 859–65PubMedCrossRefGoogle Scholar
  26. 26.
    Okada H, Watanabe Y, Kikuta T, et al. Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol 2004; 15: 2404–13PubMedCrossRefGoogle Scholar
  27. 27.
    Vandenburg MJ, Mackay EM, Dews I, et al. Dose finding studies with imidapril: a new ACE inhibitor. Br J Clin Pharmacol 1994; 37: 265–72PubMedCrossRefGoogle Scholar
  28. 28.
    van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998; 32: 1811–8PubMedCrossRefGoogle Scholar
  29. 29.
    Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 2002; 55: 113–21PubMedCrossRefGoogle Scholar
  30. 30.
    Saruta T, Omae T, Kuramochi M, et al. Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens 1995 Sep; 13Suppl. 3: S23–30CrossRefGoogle Scholar
  31. 31.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9PubMedCrossRefGoogle Scholar
  32. 32.
    Kluft C, Jie AF, Rijken DC, et al. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988; 59: 329–32PubMedGoogle Scholar
  33. 33.
    Fogari R, Zoppi A, Preti P, et al. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001; 14: 921–6PubMedCrossRefGoogle Scholar
  34. 34.
    Fogari R, Mugellini A, Zoppi A, et al. Losartan and perin-dopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316–20PubMedCrossRefGoogle Scholar
  35. 35.
    Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515–20PubMedCrossRefGoogle Scholar
  36. 36.
    Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33–50PubMedCrossRefGoogle Scholar
  37. 37.
    Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003; 34: 2922–9CrossRefGoogle Scholar
  38. 38.
    Koulouris S, Symeonides P, Triantafyllou K, et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005; 95:1386–8PubMedCrossRefGoogle Scholar
  39. 39.
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511PubMedCrossRefGoogle Scholar
  40. 40.
    Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955–9PubMedCrossRefGoogle Scholar
  41. 41.
    Ikonomidis I, Stamatelopoulos K, Lekakis J, et al. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008; 199: 3–11PubMedCrossRefGoogle Scholar
  42. 42.
    Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29–33PubMedCrossRefGoogle Scholar
  43. 43.
    Lara-Castro C, Luo N, Wallace P, et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55: 249–59PubMedCrossRefGoogle Scholar
  44. 44.
    Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 91: 1730–7CrossRefGoogle Scholar
  45. 45.
    Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81PubMedCrossRefGoogle Scholar
  46. 46.
    Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385–92PubMedCrossRefGoogle Scholar
  47. 47.
    McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–64PubMedCrossRefGoogle Scholar
  48. 48.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75PubMedCrossRefGoogle Scholar
  49. 49.
    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71PubMedCrossRefGoogle Scholar
  50. 50.
    McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47: 726–33PubMedCrossRefGoogle Scholar
  51. 51.
    Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693–704PubMedGoogle Scholar
  52. 52.
    Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angio-tensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117–24PubMedCrossRefGoogle Scholar
  53. 53.
    Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24: 486–93PubMedCrossRefGoogle Scholar
  54. 54.
    Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930–6PubMedCrossRefGoogle Scholar
  55. 55.
    ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Ken Yajima
    • 1
    • 2
  • Akira Shimada
    • 3
  • Hiroshi Hirose
    • 3
  • Yoichi Oikawa
    • 3
  • Satoru Yamada
    • 4
  • Shu Meguro
    • 5
  • Junichiro Irie
    • 3
  • Seiko Irie
    • 6
  1. 1.Department of Internal Medicine, Federation of National Public Service Personnel Mutual Aid AssociationsTachikawa HospitalTokyoJapan
  2. 2.Department of Internal MedicineHamamatsu Red Cross HospitalHamamatsu, ShizuokaJapan
  3. 3.Department of Internal MedicineKeio University School of MedicineTokyoJapan
  4. 4.Department of Internal MedicineKitasato Institute HospitalTokyoJapan
  5. 5.Department of Internal MedicineSaiseikai Central HospitalTokyoJapan
  6. 6.Department of Obstetric MedicineNational Centre for Child Health and DevelopmentTokyoJapan

Personalised recommendations